We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01087437
Recruitment Status : Unknown
Verified March 2014 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : March 16, 2010
Last Update Posted : April 1, 2014
Information provided by:

March 14, 2010
March 16, 2010
April 1, 2014
January 2011
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01087437 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Testing the Effect of Crustacean's Gastrolith Nutraceutical on Mineralization Rate During Distraction Osteogenesis
Not Provided

BACKGROUND: Distraction osteogenesis, the gradual lengthening of bones, is performed in order to equalize leg length discrepancy and correct skeletal deformities or to achieve greater height in short stature people. The femur and tibia are the bones most frequently lengthened. The surgery is currently performed at Hadassah Medical Center routinely by the pediatric orthopedic team utilizing a variety of external fixation devices.

The procedure involves application of an external fixation device to the bone, creation of an osteotomy and gradual, controlled distraction of the bone fragments On the last week of the distraction phase and every month thereafter, patients will be provided with a monthly supply of gastrolith calcium in a sealed container (65 capsules of 500 mg each, provided by Amorphical). Starting on the first day of the last week of the distraction phase, during the entire consolidation phase until the external fixator is removed; adults will orally consume two (2) 500 mg capsules a day (total of 1 gr of gastrolith calcium). Children will be given 25 mg calcium per kg body weight up to the daily adult dose of 1000mg .

Not Provided
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
  • Skeletal Deformities
  • Leg Length Discrepancy
Dietary Supplement: gastrolith calcium
Experimental: gastrolith calcium treatment
Intervention: Dietary Supplement: gastrolith calcium
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  1. Males and females
  2. Ages 4-30 years old.

Exclusion Criteria:

  1. Product Allergy
  2. Refusal to participate the study.
  3. Metabolic Disorders
Sexes Eligible for Study: All
4 Years to 30 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Ron Lamdan, Hadassah Medical Organization
Hadassah Medical Organization
Not Provided
Hadassah Medical Organization
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP